Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce results for the
first quarter ended March 31, 2009 after market trading hours on
Thursday, April 30, 2009.
A conference call to discuss first quarter ended March 31, 2009
financial results will be held on Thursday, April 30, 2009 at 5:30 p.m.
Boston time. In addition, management may answer questions concerning
business and financial developments and trends, the Company's view on
earnings forecasts, and other business and financial matters affecting
the Company. Some of the information to be presented on the call or
provided in response to questions may contain information that has not
previously been disclosed.
The conference call will be simultaneously broadcast over the Internet
and can be accessed through the Harvard Bioscience, Inc. website. To
listen to the conference call, log on to our website at www.harvardbioscience.com
and click on the Earnings Call icon. Financial and other statistical
information presented on the call, including our earnings release, will
also be available on the investor relations section of our website.
Click on the investor relations button and then click on the press
release or webcast icon, as appropriate. If you are unable to listen to
the live webcast, the call will be archived in the investor relations
section of our website. The live conference call is also accessible by
dialing 866-783-2141 and referencing the pass code of "78640960”. A
replay of this conference call will be available from 8:30 p.m. on April
30, 2009 through May 7, 2009 and will be accessible by dialing
888-286-8010 and referencing the pass code of "85099630”.
About Harvard Bioscience
Harvard Bioscience is a global developer, distributor, manufacturer and
marketer of a broad range of specialized products, primarily apparatus
and scientific instruments, used to advance life science research at
pharmaceutical and biotechnology companies, universities and government
laboratories worldwide. HBIO sells its products to thousands of
researchers in over 100 countries primarily through its 900 page catalog
(and various other specialty catalogs), its website and through its
distributors, including GE Healthcare, Thermo Fisher Scientific and VWR.
HBIO has sales and manufacturing operations in the United States, the
United Kingdom, Germany and Spain with additional facilities in France
and Canada. For more information, please visit www.harvardbioscience.com.
The statements made in this press release that are not statements of
historical fact are forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934.
These statements involve known
and unknown risks, uncertainties and other factors that may cause the
Company’s actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed
or implied by the forward-looking statements.
Factors that may
cause the Company’s actual results, performance or achievements to
differ materially from those in the forward-looking statements include,
but are not limited to, those factors set forth under the heading "Item
1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the
fiscal year ended December 31, 2008 or described in the Company’s other
public filings. The Company’s results may also be affected by factors of
which the Company is not currently aware.
The Company may not
update these forward-looking statements, even though its situation may
change in the future, unless it has obligations under the federal
securities laws to update and disclose material developments related to
previously disclosed information.
